Molecular and clinical advances in core binding factor primary acute myeloid leukemia: A paradigm for translational research in malignant hematology

Cancer Investigation

Volumn 18, Issue 8, 2000, Pages 768-780

  Marcucci, G ^a   Caligiuri, M A ^a   Bloomfield, C D ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CHROMOSOME ABERRATION; CYTOGENETICS; GENE REARRANGEMENT; HUMAN; HUMAN CELL; IN SITU HYBRIDIZATION; LEUKEMIA CELL; MALIGNANT TRANSFORMATION; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0033666432     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357900009012209     Document Type: Article

References (96)

1. Fourth International Workshop on Chromosomes in Leukemia 1982: Clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia
2. Chromosome aberrations in de novo acute myeloid leukemia in adults: Clinical implications
3. Oncogenic transcription factors in human acute leukemia
4. Molecular biology of acute myeloid leukemia
5. Clinical significance of cytogenetics in acute myeloid leukemia
6. Structural alterations in the transcription factor PEBP2/CBF linked to four different types of leukemia
7. Acute myelogenous leukemia: A disorder of gene splicing?
8. Acute leukemias with structurally altered core binding factor subunits (t(8;21), inv(16), t(12;21)), 27-28 June 1997
9. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt
10. Detection of DNA rearrangements in the AML1 and ETO loci and of an AML1/ETO fusion mRNA in patients with t(8;21) acute myeloid leukemia
11. Transcription factors, normal myeloid development, and leukemia
12. Interaction and functional cooperation of the leukemia-associated factors AML 1 and p300 in myeloid cell differentiation
13. Growth inhibition and induction of differentiation of t(8;21) acute myeloid leukemia cells by the DNA-binding domain of PEBP2 and the AML1/MTG8(ETO) specific antisense oligonucleotide
14. Characterization of the ETO and AML1-ETO proteins involved in acute myelogenous leukemia
15. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG 8 fusion transcript
16. ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: Implications for t(8;21) leukemogenesis and monitoring residual disease
17. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC 1 complex
18. Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8; 21) fusion protein may contribute to leukemogenesis
19. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis
20. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene
21. Expression of a knocked-in AML1/ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors
22. Inducible AML1 ETO expression in transgenic mice
23. Fusion between transcription factor CBFb/PEBP 2b and a myosin heavy chain in acute myeloid leukemia
24. A gene for a myosin peptide is disrupted by the inv(16)(p13q22) in acute nonlymphocytic leukemia M 4Eo
25. Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia
26. Detection of minimal residual disease in acute myelomonocytic leukemia with abnormal marrow eosinophils by nested polymerase chain reaction with allele specific amplification
27. Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia
28. Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: Rare events related to DNA-topoisomerase II inhibitors?
29. The leukemic protein core binding factor beta (CBFbeta)-smooth-muscle myosin heavy chain sequesters CBFalpha 2 into cytoskeletal filaments and aggregates
30. Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH 11
31. The CBFb subunit is essential for CBFa2 (AML1) function in vivo
32. Analysis of a conditional Cbfb-MYH11 knockin for inv(16) acute myeloid leukemia
33. Leukemia development by the induction of a second 'hit' in chimeric mice containing Cbfb/MYH11 ES cells
34. Diagnosis and monitoring of chromosome aberrations in hematological malignancies by fluorescence in situ hybridization
35. Design and validation of DNA probe sets for a comprehensive interphase cytogenetic analysis of acute myeloid leukemia
36. Molecular detection of t(8;21)/AML1-ETO in AML M1/M2: Correlation with cytogenetics, morphology and immunophenotype
37. Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials
38. Frequency of CBFb/MYH 11 fusion transcripts in patients entered into the UK MRC AML trials
39. A study to determine whether trisomy 8, deleted 9q and trisomy 22 are markers of cryptic rearrangements of PML/RARa, AML1/ETO, CBFB/MYH 11 respectively in acute myeloid leukemia
40. A comparison of cytogenetic and molecular genetic detection of t(8;21)(q22;q22) and inv(16)(p13q22) in adult de novo acute myeloid leukemia (AML): A Cancer and Leukemia Group B study
41. Overview of association between chromosome pattern and cell morphology, age, sex, and race
42. Morphological subtyping of acute myeloid leukemia with maturation (AML-M2): Homogeneous pink-colored cytoplasm of mature neutrophils is most characteristic of AML-M2 with t(8;21)
43. Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia: A unique cytogenetic-clinicopathological association
44. Is trisomy 22 in acute myeloid leukemia a primary abnormality or only a secondary change associated with inversion 16?
45. Detection of CBFb/MYH11 fusion transcripts in acute myeloid leukemia: Heterogeneity of cytological and molecular characteristics
46. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group
47. Acute myeloid leukemia with an 8;21 translocation. A report of 148 cases from the Groupe Francais de Cytogenetique Hematologique
48. Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): An additional deletion in 9q is an adverse prognostic factor
49. Age- and gender-related heterogeneity of cancer chromosome aberrations
50. Acute myeloid leukemia with translocation (8;21). Cytomorphology, dysplasia and prognostic factors in 41 cases. AML Cooperative Group and ECOG
51. Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): Results from Cancer and Leukemia Group B 8461
52. Association of granulocytosis with poor prognosis in patients with acute myelogenous leukemia and translocation of chromosomes 8 and 21
53. Secondary chromosome aberrations in acute myeloid leukemia with t(8;21)(q22; q22), inv(16)(p13q22) or t(15;17)(q22;q21)
54. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22; q22)
55. Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16
56. Chromosome 16 abnormalities associated with myeloid malignancies
57. Acute myeloid leukemia M4 with bone marrow eosinophilia (M4E0) and inv(16)(p13q22) exhibits a specific immunophenotype with CD 2 expression
58. Inv(16) acute myeloid leukemia cells show an increased sensitivity to cytosine arabinoside in vitro
59. The biological significance of the multidrug resistance gene MRP in inversion 16 leukemias
60. The t(8;21) translocation is not consistently associated with high Bcl- 2 expression in de novo acute myeloid leukemias of adults
61. Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with 'curability' of experimental leukemia
62. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: Long term follow-up and results
63. Long-term survival of patients with acute myeloid leukemia. Updated results from two trials evaluating postinduction chemotherapy
64. Intensive postremission chemotherapy in adults with acute myeloid leukemia
65. Frequency of prolonged remission duration following high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype
66. Long-term survival of patients with acute myeloid leukemia. A third follow-up of the Fourth International Workshop on Chromosomes in Leukemia
67. Adult acute myeloid leukemia (AML) patients (pts) with t(8;21)(q22;q22) have a superior outcome when repetitive cycles of high-dose cytarabine (HiDAC) are administered
68. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission
69. Karyotype in acute myeloblastic leukemia: Prognostic significance for bone marrow transplantation in first remission. A European Group for Blood and Marrow Transplantation study
70. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial
71. Outcome of acute myeloid leukemias affecting core binding factor subunits: The UK. MRC experience
72. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: Results and implications in 346 patients
73. Prospective RT-PCR monitoring of minimal residual disease in acute promyelocytic leukemia (APL) patients enrolled in the multicentric GIMEMA-AIEOP 'AIDA' trial
74. Recent Advances in the Biology and Treatment of Acute Promyelocytic Leukemia
75. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in longterm remission
76. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation
77. Detection of t(8;21) by reverse transcriptase polymerase chain reaction in patients in remission of acute myeloid leukaemia type M 2 after chemotherapy or bone marrow transplantation
78. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia
79. Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukaemia with RT-competitive PCR assay
80. Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8;21)
81. Defining the 'absence' of the CBFb/MYH11 fusion transcript in patients with acute myeloid leukemia and inversion of chromosome 16 to predict long-term complete remission: A call for definitions
82. Prognosis value of residual disease monitoring by polymerase chain reaction in patients with CBF beta/MYH11-positive acute myeloblastic leukemia
83. Detection and quantitation of the CBFbeta/MYH11 transcripts associated with the inv(16) in presentation and follow-up samples from patients with AML
84. Competitive CBFbeta/MYH11 reverse-transcription polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): A pilot study
85. Detection of the AML1/ETO fusion transcript in patients with t(8;21)-associated AML using a novel 'real time' quantitative RT-PCR assay
86. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia
87. Is translocation (8;21) a 'favorable' cytogenetic rearrangement in acute myeloid leukemia?
88. Correlation of cytogenetic results with immunophenotype, genotype, clinical features, and ras mutation in acute myeloid leukemia. A study of 235 Chinese patients in Taiwan
89. Prognostic impact of karyotype and immunologic phenotype in 125 adult patients with de novo AML
90. Certain HLA antigens are associated with specific morphologic and cytogenetic subsets of acute myeloid leukemia
91. Clinical outcome of acute myeloid leukemia (AML) involving CBF
92. Poor survival in t(8;21)(q22;q22)-associated acute myeloid leukaemia with leukocytosis
93. Prognostic significance of chromosomal abnormalities in acute nonlymphocytic leukemia: A study of 343 patients
94. Cytogenetic pattern in acute myelogenous leukemia: A major reproducible determinant of outcome
95. Inv(16) may be one of the only 'favorable' factors in acute myeloid leukemia: A report on 19 cases with prolonged follow-up